DE69202186D1 - N-substituierte-4-Phenyl-Piperidin-Opioid Antagoniste. - Google Patents

N-substituierte-4-Phenyl-Piperidin-Opioid Antagoniste.

Info

Publication number
DE69202186D1
DE69202186D1 DE69202186T DE69202186T DE69202186D1 DE 69202186 D1 DE69202186 D1 DE 69202186D1 DE 69202186 T DE69202186 T DE 69202186T DE 69202186 T DE69202186 T DE 69202186T DE 69202186 D1 DE69202186 D1 DE 69202186D1
Authority
DE
Germany
Prior art keywords
phenyl
substituted
opioid antagonists
piperidine opioid
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69202186T
Other languages
English (en)
Other versions
DE69202186T2 (de
Inventor
Buddy Eugene Cantrell
Dennis Michael Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69202186D1 publication Critical patent/DE69202186D1/de
Application granted granted Critical
Publication of DE69202186T2 publication Critical patent/DE69202186T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69202186T 1991-03-29 1992-03-27 N-substituierte-4-Phenyl-Piperidin-Opioid Antagoniste. Expired - Lifetime DE69202186T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/677,708 US5159081A (en) 1991-03-29 1991-03-29 Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists

Publications (2)

Publication Number Publication Date
DE69202186D1 true DE69202186D1 (de) 1995-06-01
DE69202186T2 DE69202186T2 (de) 1995-10-05

Family

ID=24719813

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69202186T Expired - Lifetime DE69202186T2 (de) 1991-03-29 1992-03-27 N-substituierte-4-Phenyl-Piperidin-Opioid Antagoniste.

Country Status (6)

Country Link
US (1) US5159081A (de)
EP (1) EP0506468B1 (de)
JP (1) JP3059292B2 (de)
CA (1) CA2064382C (de)
DE (1) DE69202186T2 (de)
ES (1) ES2072096T3 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5574159A (en) * 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
US5807858A (en) * 1996-06-05 1998-09-15 Delta Pharmaceutical, Inc. Compositions and methods for reducing respiratory depression
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5681830A (en) * 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
GB9202238D0 (en) * 1992-02-03 1992-03-18 Wellcome Found Compounds
DE69329894T2 (de) * 1992-12-08 2001-05-03 Ss Pharmaceutical Co., Ltd. Arylamidderivate
HU221726B1 (hu) * 1993-07-30 2002-12-28 Ardent Pharmaceuticals Inc. Piperazinszármazékok, e vegyületeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
IT1269826B (it) * 1994-05-24 1997-04-15 Paolo Minoia Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
GB9725114D0 (en) * 1997-11-28 1998-01-28 Pfizer Ltd Treatment of pruritus
WO1999045925A1 (en) * 1998-03-10 1999-09-16 Research Triangle Institute Novel opiate compounds, methods of making and methods of use
US6900228B1 (en) 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use
GB9810671D0 (en) 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
CA2334254A1 (en) * 1998-06-15 1999-12-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US6376494B1 (en) * 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US6326381B1 (en) * 1998-12-17 2001-12-04 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetrahydropyidine amide derivates
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912416D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
AU2001238690A1 (en) * 2000-03-14 2001-09-24 Sepracor, Inc. 3-substituted piperidines comprising urea functionality, and methods of use thereof
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
EA006443B1 (ru) 2000-10-30 2005-12-29 Янссен Фармацевтика Н.В. Ингибиторы трипептидил пептидазы
MXPA04003597A (es) 2001-10-18 2004-07-30 Nektar Therapeutics Al Corp Conjugados polimericos de antagonistas opiaceos.
IL161157A0 (en) 2001-10-22 2004-08-31 Pfizer Prod Inc 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
US7041681B2 (en) 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
US6794510B2 (en) 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
US20040259899A1 (en) * 2003-04-08 2004-12-23 Sanghvi Suketu P. Combination therapy for constipation
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
CN104383542B (zh) 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US20050148630A1 (en) * 2003-12-02 2005-07-07 Carpenter Randall L. Methods of preventing and treating non-opioid induced gastrointestinal dysfunction
US8946262B2 (en) * 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
US7786133B2 (en) 2003-12-16 2010-08-31 Nektar Therapeutics Chemically modified small molecules
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
US20050240177A1 (en) * 2004-04-26 2005-10-27 Packaging Service Corporation Of Kentucky Electrosurgical forceps
US7700626B2 (en) 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
JP2008528497A (ja) * 2005-01-20 2008-07-31 プロジェニックス ファーマシューティカルズ，インコーポレーテッド メチルナルトレキソンおよび関連化合物の術後性胃腸障害のための使用
US7872023B2 (en) * 2005-02-17 2011-01-18 Research Triangle Institute Kappa opioid receptor ligands
US20060211733A1 (en) * 2005-03-04 2006-09-21 Adolor Corporation Methods of preventing and treating opioid bowel dysfunction
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (es) 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AU2006265639A1 (en) * 2005-07-01 2007-01-11 Jenrin Discovery MAO-B inhibitors useful for treating obesity
US7914776B2 (en) * 2005-10-07 2011-03-29 Adolor Corporation Solid dispersions of opioid antagonists
US20070092576A1 (en) * 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
ATE516021T1 (de) * 2006-04-21 2011-07-15 Dsm Ip Assets Bv Verwendung von opioid-rezeptor-antagonisten
WO2008064351A2 (en) * 2006-11-22 2008-05-29 Progenics Pharmaceuticals, Inc. (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
PA8774201A1 (es) 2007-03-29 2009-06-23 Progenics Pharm Inc Antagonista del receptor
MX351611B (es) 2007-03-29 2017-10-20 Wyeth Llc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
SI2139890T1 (sl) 2007-03-29 2014-12-31 Wyeth Llc Antagonisti perifernih opioidnih receptorjev in njih uporaba
EP2195313B1 (de) * 2007-08-27 2014-04-02 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]oktan-verbindungen als mu-opioid-rezeptorantagonisten
ES2390195T3 (es) * 2007-08-27 2012-11-07 Theravance, Inc. Compuestos de amidoalquil-8-azabiciclo(3,2,1)octano, como antagonistas del receptor opioide mu
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
WO2009029257A1 (en) 2007-08-27 2009-03-05 Theravance, Inc. Disubstituted alkyl-8-azabicyclo [3.2.1.] octane compounds as mu opioid receptor antagonists
EP2730578A1 (de) 2008-02-06 2014-05-14 Progenics Pharmaceuticals, Inc. Herstellung und Verwendung von (R),(R)-2,2'-bis-methylnaltrexon
EP2278966B1 (de) 2008-03-21 2019-10-09 The University of Chicago Behandlung mit opioid-antagonisten und mtor-inhibitoren
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US20100311782A1 (en) 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
NZ598783A (en) * 2009-09-18 2013-07-26 Adolor Corp Use of opioid receptor antagonist for gastrointestinal tract disorders
NZ600379A (en) 2009-12-04 2014-05-30 Alkermes Pharma Ireland Ltd Morphinan derivatives for the treatment of drug overdose
ES2533990T3 (es) 2010-02-24 2015-04-16 Research Triangle Institute Antagonistas de receptores opioides de arilpiperazina
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US9629566B2 (en) 2011-03-11 2017-04-25 Spacelabs Healthcare Llc Methods and systems to determine multi-parameter managed alarm hierarchy during patient monitoring
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
GB2545368B (en) 2014-10-20 2021-04-21 Elysium Therapeutics Inc Diversion-resistant opioid formulations
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
WO2017059459A1 (en) 2015-10-01 2017-04-06 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
EP3595663A4 (de) 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. Mehrfachuntereinheit-opioid-prodrugs mit resistenz gegen überdosierung und missbrauch
US11365191B2 (en) 2018-02-28 2022-06-21 Dart Neuroscience, Llc Substituted cyclohexyl compounds as NOP inhibiiors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3936468A (en) * 1969-10-27 1976-02-03 Sumitomo Chemical Company, Ltd. Phenylbutanol derivatives
AR205452A1 (es) * 1973-12-06 1976-05-07 Endo Lab Metodo para preparar nuevos trans-2, 3, 4, 4a, 5, 9b-hexahidro-5-fenil-1h-pirido(4,3-b) indoles
US4191771A (en) * 1974-09-06 1980-03-04 Eli Lilly And Company Analgesic method using 1,3,4-trisubstituted-4-arylpiperidines
AR206937A1 (es) * 1974-09-06 1976-08-31 Lilly Co Eli Procedimiento para preparar compuestos de 1-sustituido-4-alquil-4-fenil-piperidina
US4175197A (en) * 1974-09-06 1979-11-20 Eli Lilly And Company 1,3,4-Trisubstituted-4-aryl-1,4,5,6-tetra-hydropyridines
SE7702301L (sv) * 1976-04-08 1977-10-09 Endo Lab Trans-hexahydro-pyrido-indoler
US4115400A (en) * 1976-05-27 1978-09-19 Eli Lilly And Company 1-Azoniabicyclo[3.1.0]hexanes
US4284635A (en) * 1978-11-29 1981-08-18 Eli Lilly And Company Analgesic 1,2,4,5-tetra-alkyl-4-arylpiperidines
US4663460A (en) * 1983-09-21 1987-05-05 Eli Lilly And Company Intermediates for picenadol
US4581456A (en) * 1983-09-21 1986-04-08 Eli Lilly And Company Processes for preparing picenadol precursors and novel intermediates thereof
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
US4992450A (en) * 1987-04-16 1991-02-12 Eli Lilly And Company Piperidine opioid antagonists

Also Published As

Publication number Publication date
EP0506468B1 (de) 1995-04-26
DE69202186T2 (de) 1995-10-05
CA2064382C (en) 2005-07-05
JPH0597807A (ja) 1993-04-20
US5159081A (en) 1992-10-27
ES2072096T3 (es) 1995-07-01
CA2064382A1 (en) 1992-09-30
EP0506468A1 (de) 1992-09-30
JP3059292B2 (ja) 2000-07-04

Similar Documents

Publication Publication Date Title
DE69202186D1 (de) N-substituierte-4-Phenyl-Piperidin-Opioid Antagoniste.
FI924405A0 (fi) Lhrh-antagonister.
FI922201A0 (fi) Rapamycinamidestrar.
DE122006000020I1 (de) Aerosolpraparate.
FI914417A0 (fi) Effektdetektor.
DE69206353D1 (de) Anlasser.
NO910466L (no) Sjoevanncelle.
DE59201883D1 (de) Tilger.
PH31071A (en) Substituted pyrridopyrimidines useful antgiotensinII antagonists.
DE69204920D1 (de) Angiotensin-II-Antagoniste.
DE69206522D1 (de) Vibrator.
ES1016723Y (es) Boligrafo-pulverizador mejorado.
FI921786A0 (fi) Farmaceutisk foerening.
DE59105384D1 (de) Anomaloskop.
FI921785A0 (fi) Farmaceutisk foerening.
FI930108A0 (fi) Imidazopyridin-paf-antagonister
FI914895A0 (fi) Under undertryck fungerande torkningsenhet foer en pappersmaskin.
ITMT910002A0 (it) Europa - time - c.e.e.
ITMT910001V0 (it) Europa - time - c.e.e.
ES1018067Y (es) Tarjeta-puzzle.
ES1017798Y (es) Garfio-soporte.
ES1017618Y (es) Flexometro-trazador.
ES1018229Y (es) Bovedilla.
ES1019520Y (es) Lapida funeraria.
ES1018322Y (es) Hidrocompresor.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN